ImmunityBio shares plunge 21.7% on Q3 earnings miss despite regulatory wins
The biotech’s stock dropped sharply as a wider net loss and revenue miss overshadowed 53% revenue growth and new Israeli approvals.
The biotech’s stock dropped sharply as a wider net loss and revenue miss overshadowed 53% revenue growth and new Israeli approvals. Published 2026-11-09 by Falling Shares.
| By Falling Shares Intelligence, edited by Wung Thomas, Editor-in-Chief
Written by Falling Shares Intelligence, our automated newsroom, from the public sources listed below and live market data. Every figure is checked against that material before publication, but the story has not been reviewed by a human editor. Check the linked sources before relying on it, and report errors to info@fallingshares.com.
ImmunityBio shares fell 21.7% on Monday after the company reported a wider third-quarter net loss that missed analyst estimates, offsetting gains from rising revenue and new product approvals. The drop left the stock 40% below its 52-week high.
Earnings miss outweighs revenue growth
ImmunityBio reported a third-quarter net loss that widened compared to the previous year, according to MT Newswires and Zacks. The company’s net product revenue rose 53% year-over-year to $48.7 million, with first-nine-month U.S. revenue increasing 92% to $143.6 million, as stated in a Business Wire filing.
Despite the sales growth, the company missed revenue estimates for the quarter, according to Zacks and Associated Press. Stocktwits users noted the earnings miss drove the stock to near nine-month lows, with some retail investors expressing concern about further dilution.
The stock’s volatility remains high, with Falling Shares rating it Unstable due to an annualised volatility of 86.2% compared to 14.3% for the benchmark. The company has missed earnings per share estimates in three of the last four quarters, according to Falling Shares risk signals.
Regulatory wins fail to stabilise price
The share price decline occurred even as the company announced regulatory progress. ImmunityBio and Rafa Laboratories received approval from the Israeli Ministry of Health for Anktiva, according to MT Newswires.
Business Wire reported that the approval covers ANKTIVA Plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The company also noted a label expansion for the product.
Blockonomi reported that the stock fell 18% despite the cancer trial win and sales growth, though Falling Shares data shows the actual fall was 21.7% in the latest session. The company’s market capitalisation stands at 7.17 billion USD.